AUC AND cmax ARE NOT SUFFICIENT TO PROVE BIOEQUIVALENCE

ISSN： 1043-6618

Source： Pharmacological Research, Vol.37, Iss.2, 1998-02, pp. : 93-95

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Orlistat reduces the maximum plasma concentration (Cmax) and AUC0-12 of cyclosporin

Inpharma, Vol. 1, Iss. 1361, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Use of Partial AUC to Demonstrate Bioequivalence of Zolpidem Tartrate Extended Release Formulations

By Lionberger Robert Raw Andre Kim Stephanie Zhang Xinyuan Yu Lawrence

Pharmaceutical Research, Vol. 29, Iss. 4, 2012-04 ,pp. : 1110-1120

Springer Publishing Company

Access to resources Recommend Favorite

On the Determination of Bioequivalence

By Farolfi M. Powers J.D. Rescigno A.

Pharmacological Research, Vol. 39, Iss. 1, 1999-01 ,pp. : 1-4

Academic Press

Access to resources Recommend Favorite

Bioequivalence and Pharmacogenetics

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 11, Iss. 4, 2013-12 ,pp. : 288-294

Bentham Science Publishers

Access to resources Recommend Favorite

An AUC-Like Index for Agreement Assessment

Journal of Biopharmaceutical Statistics, Vol. 24, Iss. 4, 2014-07 ,pp. : 893-907

Taylor & Francis Ltd

Access to resources Recommend Favorite